Verdiva Bio Brings Oral Amylin VRB-103 and a GLP-1/Amylin Co-Agonist to ADA 2026 With Preclinical Data
Verdiva Bio will present two posters at ADA 2026 on its obesity pipeline: VRB-103, a once-weekly oral amylin-receptor-selective analog, and VRB-104, a unimolecular GLP-1 plus amylin co-agonist. The preclinical data extend the amylin and oral-peptide push from a well-funded newer entrant, as the obesity field broadens beyond incretin monotherapy toward amylin-based and oral approaches.